Clinician Scientist’s Perspective – Interpreting the Latest IPF Clinical Trial Readouts: What Do They Mean for Patients & the Future of Drug Development?
- Breaking down recent Phase II/III trial outcomes and approvals through a clinician’s lens, examining how efficacy signals, safety profiles, and real-world tolerability translate into meaningful benefit for patients in routine practice
- Understanding what these results reveal about mechanisms that are (and aren’t) working, and how emerging data are reshaping expectations around endpoints, disease modification, and what constitutes clinically meaningful improvement in IPF
- Looking ahead to the next generation of trials, exploring how recent successes and failures should inform study design, patient selection, combination strategies, and the evolving role of standard-of-care in future development programs